On March 13th, RudaCure and Hanlim Pharmaceutical held an advisory meeting for Phase 2 ensayo clínicos of their tratamiento de la enfermedad de ojo seco, inviting 13 ophthalmology clinical experts.
At the advisory meeting celebrado en the Mondrian Hotel, with the assistance of Hanlim Pharmaceutical's mercadoing department, 13 anterior segment ophthalmology professors from across the país were invited to share proyecto descriptions and Phase 1 ensayo clínico progreso for RCI001/HL262, and to receive advice for successfully conducting Phase 2 ensayo clínicos.
Agradecemos sinceramente a all the professors and Hanlim Pharmaceutical colleagues who asistió, and we will do our best to achieve resultados that meet everyone's expectations.